TABLE 3

Use of medication, asthma attacks and healthcare utilisation during the last 12 months in subjects with persistent asthma#

ECRHS IECRHS IIECRHS IIIChange in prevalence
Inhaled SABA68.667.558.0−10.1 (−15.5– −4.7)
Inhaled LABAs14.840.425.3 (19.5–31.1)
ICSs31.446.249.117.2 (11.6–22.9)
ICSs used daily in the last 3 months18.826.332.813.5 (8.6–18.3)
ICS+LABA12.736.423.5 (17.9–29.0)
Inhaled anticholinergics2.62.33.71.0 (−1.5–3.4)
Theophylline13.02.90.3−12.5 (−15.9–9.1)
Oral β2-agonists7.51.70−7.5+
LTRAs3.37.13.7 (0.07–6.7)
OCSs8.89.16.7−1.6 (−5.1–1.9)
Any medication for asthma72.976.973.91.2 (3.2–5.7)
Hospitalisations2.21.51.2−1.1 (−3.0–0.8)
At least one asthma attack in the last 12 months68.851.040.9−27.9 (−33.7– −22.1)
Three or more asthma attacks in the last 12 months46.535.825.8−20.8 (−26.5– −15.0)
Doctor visit for breathing problems in the last 12 months41.734.342.30.6 (−5.7–6.9)

Data are presented as % or % (95% CI). ECRHS: European Community Respiratory Health Survey; SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid. #: n=369; : as a single inhaler or in combination; +: not possible to calculate 95% confidence interval.